Microbot Medical Inc. (MBOT)
| Market Cap | 63.99M -51.9% |
| Revenue (ttm) | 346,000 |
| Net Income | -16.34M |
| EPS | -0.26 |
| Shares Out | 67.16M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 387,474 |
| Open | 0.9500 |
| Previous Close | 0.9500 |
| Day's Range | 0.9440 - 0.9730 |
| 52-Week Range | 0.9300 - 2.8900 |
| Beta | 1.05 |
| Analysts | Strong Buy |
| Price Target | 6.33 (+564.36%) |
| Est. Earnings | Nov 11, 2026 |
About MBOT
Microbot Medical Inc. is a medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system designed to maneuver guidewires and over-the-wire devices, such as microcatheters within the body’s vasculature for use in cardiovascular, peripheral, endovascular, and neurovascular operations. It also provides NovaCross, an intellectual property and technology in the field of intraluminal rev... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for MBOT stock is "Strong Buy." The 12-month stock price target is $6.33, which is an increase of 564.36% from the latest price.
News
Microbot Medical signs exclusive commercial distribution pact with Medtechnica
Microbot Medical (MBOT) announced that it has signed a three-year exclusive commercial distribution agreement with Medtechnica to market and sell the company’s Liberty System in Israel. The company re...
Microbot Medical® and Medtechnica Ltd. Enter into Three-Year Exclusive Distribution Agreement in Israel
Medtechnica Ltd., a Leading Medical Device Distributor in Israel, Authorized to Distribute the LIBERTY® Endovascular Robotic System Throughout Israel Microbot Medical is Executing its International Ma...
Microbot Medical® Highlights Growth Strategy
Service Unavailable Service Unavailable HTTP Error 503. The service is unavailable.
Microbot Medical price target lowered to $3 from $4 at Lucid Capital
Lucid Capital analyst Alex Nowak lowered the firm’s price target on Microbot Medical (MBOT) to $3 from $4 and keeps a Buy rating on the shares following the analyst event.
Microbot Medical transferred with Buy rating at B. Riley
B. Riley analyst William Wood kept a Buy rating on Microbot Medical (MBOT) with a $4 price target following a transfer of coverage. The company commercializes Liberty, the first and…
Microbot Medical price target lowered to $4 from $5 at B. Riley
B. Riley lowered the firm’s price target on Microbot Medical (MBOT) to $4 from $5 and keeps a Buy rating on the shares. Microbot Medical’s Q2 revenue missed expectations as…
Microbot Medical® Files 10-Q, Reports Significant Revenue and Customer Growth During the 2026 Second Quarter
Revenue increased by more than 100% over the prior fiscal quarter, driven by repeat orders, expanded utilization among existing customers, and the acquisition of new customers since the Full Market Re...
Microbot Medical Quarterly report: Q2 2026
Microbot Medical has published its Q2 2026 quarterly earnings report on August 11, 2026.
Microbot Medical Earnings release: Q2 2026
Microbot Medical released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Microbot Medical® Among Featured Companies Showcasing Novel Robotic Technologies and Digital Surgery Applications at the Society of Robotic Surgery Annual Meeting
HINGHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, will be participating at this ...
Microbot Medical® Reports Over 100% Revenue and Customer Growth as Procedure Volume Also Rises in the Second Quarter of 2026
The Company is experiencing rising demand and increasing pipeline for the LIBERTY System since commencing the Full Market Release in April Heightened awareness generating interest from leading health ...
Microbot Medical increases manufacturing capacity for Liberty System
Microbot Medical (MBOT) has entered into a letter of agreement with Sanmina Corporation to manufacture the Liberty System. The company believes it is necessary to expand its manufacturing capacity to…
Microbot Medical® Increases Manufacturing Capacity as Demand for the LIBERTY® System Rises; Enters into Strategic Agreement with Sanmina, a Global Manufacturing Leader
HINGHAM, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, has entered into a Letter of A...
Microbot Medical® Wins Surgical Robotics Industry Award for the LIBERTY® Endovascular Robotic System
HINGHAM, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it has won the ...
Microbot Medical® Announces First Health System in Pennsylvania to Adopt the LIBERTY® Endovascular Robotic System
Leading academic center with multi-hospital and multi-state health system deepens Company's footprint in the Northeast U.S. The Company now has multiple accounts and hospitals that have adopted the LI...
Microbot Medical management to meet virtually with B. Riley
Virtual Meeting to be held on June 23 hosted by B. Riley.
Microbot enters federal healthcare systems pact with Lovell Government Services
Microbot Medical (MBOT) has entered into an agreement with Lovell Government Services to serve federal healthcare systems, such as those administered by the Veterans Health Administration, a division ...
Microbot Medical® Enters Into an Agreement to Expand Access for America's Veteran and Military Patient Populations
HINGHAM, Mass., June 16, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, has entered into an agreement ...
Microbot Medical® Announces a Notable Health System as the First in Michigan to Adopt the LIBERTY® Endovascular Robotic System
HINGHAM, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that one of the larg...
Microbot Medical initiated with a Buy at Lucid Capital
Lucid Capital analyst Alex Nowak initiated coverage of Microbot Medical (MBOT) with a Buy rating and $4 price target The company’s Liberty robot system is a “novel approach in a…
Microbot Medical® Secures the First Healthcare System in North Carolina to Adopt the LIBERTY® Endovascular Robotic System
HINGHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it has secured ...
Microbot Medical announces Israel granted marketing clearance for Liberty
Microbot Medical (MBOT) announced that it has achieved a significant regulatory milestone as Israel becomes the second jurisdiction – and the first outside of the U.S. – to grant marketing…
Microbot Medical® Receives Its First International Regulatory Approval for the Commercialization of the LIBERTY® Endovascular Robotic System
Israel becomes the second jurisdiction and the first outside of the U.S. to grant marketing clearance for the LIBERTY System The AMAR regulatory approval will enable the Company to obtain a Free Sale ...
Microbot Medical to Hold Analysts and Investors Conference Call to Review Recent Progress; Executive Team will be Joined by Current Users of the LIBERTY Endovascular Robotic System, Dr. Charles Briggs and Dr. Zachary Bercu
Microbot to Hold Conference Call to Review Recent Progress; Executive Team to be Joined by Current LIBERTY Users, Dr. Charles Briggs and Dr. Zachary Bercu
Microbot Medical Successfully Transitions to Commercial Operations as It Records Revenue Resulting from Its Limited Market Release During the First Quarter of 2026
Recent transition to the Full Market Release has already resulted in increased revenue for the current Q2, which has already exceeded Q1 revenue, as utilization and adoption of the LIBERTY System acce...